Document is current

Article History

Received: 5 June 2023

Accepted: 24 August 2023

First Online: 26 September 2023

Declarations

:

: This study was approved by the Comité de Protection des Personnes du Sud-Est 5 (RCB ID: 2019-A02637-50). Written informed consent was obtained from all patients’ relatives before inclusion. The study was registered on ClinicalTrials.gov (NCT04613752) prior inclusion of the first patient.

: Not applicable.

: Martin Dres received personal fees from Lungpacer Medical Inc., Vancouver, Canada, support for attending meetings and/or travel from Lungpacer, outside the submitted work. Alexandre Demoule reports grants from the French Ministry of Health, Assistance publique–Hôpitaux de Paris, Lungpacer, Respinor, consulting fees from Respinor, Lungpace, Lowenstein, Tribunal administrative de Cergy, Liberate Medical, Payment or honoraria for lectures, presentations from Fisher & Paykel, Baxter, Getinge, Astra, Agence Européenne Informatique, Mindray, support for attending meetings and/or travel from Lungpacer, outside the submitted work. Thomas Similowski reports personal fees for consulting and teaching activities from ADEP Assistance, AstraZeneca France, Chiesi France, KPL consulting, Lungpacer Inc., OSO-AI, TEVA France, Vitalaire. He is a stock shareholder of startups Hephaï and Austral Dx. He is listed as an inventor on issued patents (WO2008006963A3, WO2012004534A1, WO2013164462A1) describing EEG responses to experimental and clinical dyspnea. Matthieu Schmidt reports lecture fees from Getinge, Drager, and Xenios outside the submitted work. Alain Combes reports grants from Getinge, and personal fees from Getinge, Baxter, and Xenios outside the submitted work. The other authors declare that they have no conflict of interest.